KR100310510B1 - 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 - Google Patents
3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 Download PDFInfo
- Publication number
- KR100310510B1 KR100310510B1 KR1019950704133A KR19950704133A KR100310510B1 KR 100310510 B1 KR100310510 B1 KR 100310510B1 KR 1019950704133 A KR1019950704133 A KR 1019950704133A KR 19950704133 A KR19950704133 A KR 19950704133A KR 100310510 B1 KR100310510 B1 KR 100310510B1
- Authority
- KR
- South Korea
- Prior art keywords
- mpl
- antigen
- vaccine composition
- particles
- monophosphoryl lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940035032 monophosphoryl lipid a Drugs 0.000 title claims abstract description 234
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- 229960005486 vaccine Drugs 0.000 title claims abstract description 87
- 239000002245 particle Substances 0.000 claims abstract description 89
- 239000000427 antigen Substances 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 239000000725 suspension Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- 208000005252 hepatitis A Diseases 0.000 claims description 12
- 208000002672 hepatitis B Diseases 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 8
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 8
- 108700006640 OspA Proteins 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 229940029583 inactivated polio vaccine Drugs 0.000 claims description 6
- 238000000527 sonication Methods 0.000 claims description 6
- 241000700721 Hepatitis B virus Species 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- 238000011084 recovery Methods 0.000 claims description 5
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 101710137302 Surface antigen S Proteins 0.000 claims description 4
- 206010043376 Tetanus Diseases 0.000 claims description 4
- 206010013023 diphtheria Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 238000003860 storage Methods 0.000 claims description 4
- 102100031673 Corneodesmosin Human genes 0.000 claims description 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 208000000474 Poliomyelitis Diseases 0.000 claims description 2
- 229940096437 Protein S Drugs 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 239000011246 composite particle Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 9
- 230000001571 immunoadjuvant effect Effects 0.000 claims 7
- 239000000568 immunological adjuvant Substances 0.000 claims 7
- 239000007900 aqueous suspension Substances 0.000 claims 6
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims 2
- -1 polyoxyethylene Polymers 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 230000004044 response Effects 0.000 description 23
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 201000010099 disease Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 230000000306 recurrent effect Effects 0.000 description 21
- 230000003053 immunization Effects 0.000 description 20
- 238000002649 immunization Methods 0.000 description 20
- 230000006698 induction Effects 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 241000700198 Cavia Species 0.000 description 16
- 238000002255 vaccination Methods 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 230000005847 immunogenicity Effects 0.000 description 15
- 230000005951 type IV hypersensitivity Effects 0.000 description 15
- 102000000588 Interleukin-2 Human genes 0.000 description 14
- 108010002350 Interleukin-2 Proteins 0.000 description 14
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 14
- 230000003472 neutralizing effect Effects 0.000 description 14
- 230000028327 secretion Effects 0.000 description 14
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 14
- 241000709721 Hepatovirus A Species 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000282693 Cercopithecidae Species 0.000 description 9
- 241000288906 Primates Species 0.000 description 9
- 230000024932 T cell mediated immunity Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000000447 Th1 cell Anatomy 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000004727 humoral immunity Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000000908 micropen lithography Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 229940124914 Havrix Drugs 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229960002520 hepatitis vaccine Drugs 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 241000282552 Chlorocebus aethiops Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- 238000002296 dynamic light scattering Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000011554 guinea pig model Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229940021747 therapeutic vaccine Drugs 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 241000589968 Borrelia Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 229940124884 Engerix-B Drugs 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000022555 Genital disease Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940042470 lyme disease vaccine Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (55)
- 항원, 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자, 및 적합한 담체를 포함하는 멸균 백신 조성물로서, 3D-MPL의 입자 크기가 대체로 120㎚ 이하인 백신 조성물.
- 제 1항에 있어서, MPL의 입자 크기가 60 내지 120㎚ 범위인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, MPL의 입자 크기가 100㎚ 미만인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 담체가 수산화알루미늄인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 담체가 수중유 에멀션 또는 기타의 지질 기초 부형제인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 바이러스 항원을 포함하는 것을 특징으로 하는 백신 조성물.
- 제 6항에 있어서, 항원이 A형 간염 항원인 것을 특징으로 하는 백신 조성물.
- 제 7항에 있어서, A형 간염 항원이 HM-175 균주로부터 유래하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 항원에 B형 간염 항원인 것을 특징으로 하는 백신 조성물.
- 제 9항에 있어서, 항원이 B형 간염 표면 항원(HBsAg) 또는 그의 변이체인 것을 특징으로 하는 백신 조성물.
- 제 9항에 있어서, A형 간염 항원을 추가로 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 항원이 HBsAg이고, HBsAg의 S 항원을 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 항원이 B형 간염 바이러스로부터의 표면 항원이고, 프레-S 서열 및 S 항원을 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 항원이 B형 간염 바이러스의 L-단백질의 12 내지 52 잔기, 그 다음에 133 내지 145 잔기, 그 다음에 175 내지 400 잔기로 이루어진 아미노산 서열을 갖는 변형 L-단백질, 및 HBsAg의 S-단백질을 함유하는 복합 입자인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 하나 이상의 간염 항원, 및 디프테리아, 파상풍, 백일해, 해모필루스 인플루엔자 b(Hib) 및 소아마비 중의 하나 이상에 대해 방어를 제공하는 비-간염 항원으로부터 선택된 하나 이상의 기타 성분을 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, DTP(디프테리아-파상풍-백일해) HBsAg 복합체, Hib-HBsAg 복합체, DTP-Hib-HBsAg 복합체 및 IPV(불활성화 소아마비 백신)-DTP-Hib-HBsAg 복합체로부터 선택된 항원을 포함하는 것을 특징으로 하는 백신 조성물.
- 제 16항에 있어서, A형 간염 항원을 추가로 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, HSV 당단백질 D 또는 이것의 면역학적 단편을 포함하는 것을 특징으로 하는 백신 조성물.
- 제 18항에 있어서, 당단백질 D가 절단된 단백질인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 항원이 HSVgD2항원이고 C 말단 고정 영역이 없는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 3-O-탈아실화 모노포스포릴 지질 A가 투여량 당 10㎍ 내지 100㎍의 범위로 존재하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 폴리옥시에틸렌(20) 소르비탄 포노-올리에이트 또는 소르비톨을 추가로 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 항원이 가용성 NS1-OspA 융합 단백질이고, NS1이 인플루엔자 NS1이며, OspA가 보렐리아 버그도르페리(Borrelia burgdorferi) OspA인 것을 특징으로 하는 백신 조성물.
- 제 23항에 있어서, 융합 단백질이 수산화알루미늄에 흡착된 것을 특징으로 하는 백신 조성물.
- 입자 크기가 120㎚ 미만인 3-O-탈아실화 포노포스포릴 지질 A.
- 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL)의 입자 크기가 대체로 120㎚ 이하인 멸균 수성 현탁액.
- 제 26항에 있어서, 여과 멸균되었음을 특징으로 하는 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자의 현탁액.
- 제 27항에 있어서, 220㎚ 친수성 막을 통해 여과 멸균되었음을 특징으로 하는 3D-MPL 입자의 현탁액.
- 제 27항에 있어서, 2℃ 내지 8℃에서 저장할 때 안정한 것을 특징으로 하는 3D-MPL 입자의 현탁액.
- 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자를 물에 현탁시키는 단계, 및 수득한 현탁액내 3D-MPL 입자의 크기를 현탁액이 투명해질 때까지 감소시키는 단계를 포함하는, 3-O-탈아실화 모노포스포릴 지질 A 입자의 투명한 수성 현탁액의 제조방법.
- 제 30항에 있어서, 투명한 현탁액을 220㎚ 친수성 막을 통해 여과 멸균시켜,3D-MPL 입자의 투명한 수성 멸균 현탁액을 수득하는 단계를 추가로 포함하는 방법.
- 제 30항에 있어서, 3D-MPL 입자 크기의 감소가 초음파처리에 의하는 것을 특징으로 하는 방법.
- 제 30항의 방법에 의해 수득한 생성물인 투명한 수성 현탁액.
- 입자 크기가 대체로 120㎚ 이하인 3-O-탈아실화 모노포스포릴 지질 A 입자의 투명한 수성 멸균 현탁액을 항원과 혼합하고, 항원이 수산화알루미늄에 흡착되는 단계를 포함하는 백신의 제조방법.
- 감염의 예방 또는 치료용 항원 함유 의약의 제조방법에 있어서, 상기 항원을 입자 크기가 120㎚ 이하인 3-O-탈아실화 모노포스포릴 지질 A 와 혼합하는 단계를 포함하는 것을 특징으로 하는 방법.
- 멸균 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자, 수산화알루미늄, 및 항원의 상호작용 생성물을 포함하며, MPL 입자가 220㎚ 친수성 막을 통해 여과 멸균된 백신 조성물.
- 제 36항에 있어서, 항원이 A형 간염 항원인 것을 특징으로 하는 백신 조성물.
- 제 36항에 있어서, 항원이 B형 간염 항원인 것을 특징으로 하는 백신 조성물.
- 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자의 안정한 수성 현탁액을 포함하는 면역보강 조성물로서, 3D-MPL의 입자 크기가 220㎚ 친수성 막을 통해 여과가능할 정도로 작은 면역보강 조성물.
- 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자의 여과된 안정한 수성 현탁액을 포함하는 멸균 면역보강 조성물로서, 상기 입자의 220㎚ 친수성 막을 통한 여과 회수율이 78.5% 이상인 면역보강 조성물.
- 제 40항에 있어서, 항원을 포함하는 것을 특징으로 하는 면역보강 조성물.
- 제 41항에 있어서, 항원이 수산화알루미늄에 흡착된 것을 특징으로 하는 면역보강 조성물.
- 220㎚ 친수성 막을 통해 여과된 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자로 본질적으로 구성된 안정한 수성 현탁액을 포함하는 멸균 면역보강 조성물.
- 제 43항에 있어서, 항원을 포항하는 것을 특징으로 하는 면역보강 조성물.
- 제 44항에 있어서, 항원이 수산화알루미늄에 흡착된 것을 특징으로 하는 면역보강 조성물.
- 항원, 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자 및 적합한 담체를 포함하는 멸균 백신 조성물로서, 3D-MPL 입자가 220㎚ 친수성 막을 통한 여과의 회수물인 멸균 백신 조성물.
- 제 46항에 있어서, 담체가 수산화알루미늄인 것을 특징으로 하는 백신 조성물.
- 항원, 약학적으로 허용되는 담체, 및 크기가 100㎚ 미만인 입자로 본질적으로 구성된 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL)를 포함하는 멸균 백신 조성물.
- 제 48항에 있어서, 담체가 수산화알루미늄인 것을 특징으로 하는 백신 조성물.
- 제 49항에 있어서, 항원이 HBsAg인 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, 면역자극제를 추가로 포함하는 것을 특징으로 하는 백신 조성물.
- 제 1항에 있어서, QS21을 추가로 포함하는 것을 특징으로 하는 백신 조성물.
- 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL)를 수성 매질에서 트리에틸아민(TEA)의 부재하에 현탁시키는 단계를 포함하는, 3D-MPL 입자를 포함하는 면역보강 조성물의 제조방법에 있어서, 실질적으로 모든 3D-MPL 입자가 220㎚ 친수성 막을 통해 여과가능한 것을 특징으로 하는 방법.
- 220㎚ 막을 통해 여과가능하고, 3-O-탈아실화 모노포스포릴 지질 A를 주사용 물중에서 초음파처리하는 단계로 구성된 방법에 의해 수득가능한 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자.
- 220㎚ 막을 통해 여과가능하고, 3-O-탈아실화 모노포스포릴 지질 A를 물중에서 트리에틸아민의 부재하에 초음파처리하는 단계로 구성된 방법에 의해 수득가능한 3-O-탈아실화 모노포스포릴 지질 A(3D-MPL) 입자.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939306029A GB9306029D0 (en) | 1993-03-23 | 1993-03-23 | Vaccine compositions |
GB9306029.1 | 1993-03-23 | ||
GB9403417A GB9403417D0 (en) | 1994-02-23 | 1994-02-23 | Vaccine compositions |
GB9403417.0 | 1994-02-23 | ||
PCT/EP1994/000818 WO1994021292A1 (en) | 1993-03-23 | 1994-03-14 | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100310510B1 true KR100310510B1 (ko) | 2002-07-04 |
Family
ID=26302633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950704133A Expired - Lifetime KR100310510B1 (ko) | 1993-03-23 | 1994-03-14 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
Country Status (28)
Country | Link |
---|---|
US (1) | US5776468A (ko) |
EP (3) | EP0812593B8 (ko) |
JP (2) | JP4028593B2 (ko) |
KR (1) | KR100310510B1 (ko) |
CN (1) | CN1087176C (ko) |
AP (1) | AP515A (ko) |
AT (2) | ATE157882T1 (ko) |
AU (1) | AU685443B2 (ko) |
BR (1) | BR9405957A (ko) |
CZ (1) | CZ289476B6 (ko) |
DE (2) | DE69405551T3 (ko) |
DK (2) | DK0812593T4 (ko) |
DZ (1) | DZ1763A1 (ko) |
ES (2) | ES2162139T5 (ko) |
FI (1) | FI110844B (ko) |
GR (1) | GR3025483T3 (ko) |
HK (1) | HK1045935A1 (ko) |
HU (1) | HU219056B (ko) |
IL (1) | IL109056A (ko) |
MA (1) | MA23143A1 (ko) |
NO (2) | NO322578B1 (ko) |
NZ (1) | NZ263538A (ko) |
PL (1) | PL178578B1 (ko) |
PT (1) | PT812593E (ko) |
SA (1) | SA94140762B1 (ko) |
SG (1) | SG48309A1 (ko) |
SK (1) | SK117395A3 (ko) |
WO (1) | WO1994021292A1 (ko) |
Families Citing this family (440)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
US6620414B2 (en) * | 1992-03-27 | 2003-09-16 | Smithkline Beecham Biologicals (S.A.) | Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A |
ES2118963T3 (es) * | 1992-05-23 | 1998-10-01 | Smithkline Beecham Biolog | Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos. |
WO1994027636A1 (en) * | 1993-05-25 | 1994-12-08 | American Cyanamid Company | Adjuvants for vaccines against respiratory syncytial virus |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6696065B1 (en) * | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
AU1463097A (en) | 1996-01-04 | 1997-08-01 | Rican Limited | Helicobacter pylori bacterioferritin |
US20030185830A1 (en) * | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20060269532A1 (en) * | 1997-02-25 | 2006-11-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
US20060024301A1 (en) * | 1997-02-25 | 2006-02-02 | Corixa Corporation | Prostate-specific polypeptides and fusion polypeptides thereof |
US7517952B1 (en) * | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
BR9811262A (pt) * | 1997-04-01 | 2000-10-17 | Ribi Immunochem Research Inc | Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a. |
US6491919B2 (en) * | 1997-04-01 | 2002-12-10 | Corixa Corporation | Aqueous immunologic adjuvant compostions of monophosphoryl lipid A |
GB9706957D0 (en) * | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
US6368604B1 (en) * | 1997-09-26 | 2002-04-09 | University Of Maryland Biotechnology Institute | Non-pyrogenic derivatives of lipid A |
GB9724531D0 (en) | 1997-11-19 | 1998-01-21 | Smithkline Biolog | Novel compounds |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
CA2332979A1 (en) * | 1998-05-22 | 1999-12-02 | Smithkline Beecham Biologicals S.A. | Correlative protection using ospa antibody titers |
ES2229745T3 (es) * | 1998-07-14 | 2005-04-16 | Wyeth Holdings Corporation | Composicionde adyuvante y vacuna que contienen monofosforil lipido a. |
US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
US20040213806A1 (en) * | 1998-08-28 | 2004-10-28 | Smithkline Beecham Biologicals, S.A. | Salmonella typhi vaccine compositions |
US6692752B1 (en) | 1999-09-08 | 2004-02-17 | Smithkline Beecham Biologicals S.A. | Methods of treating human females susceptible to HSV infection |
GB9819898D0 (en) * | 1998-09-11 | 1998-11-04 | Smithkline Beecham Plc | New vaccine and method of use |
GB9820525D0 (en) * | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
GB9822714D0 (en) | 1998-10-16 | 1998-12-09 | Smithkline Beecham Sa | Vaccines |
DE122007000087I1 (de) * | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
EP1137777B1 (en) | 1998-12-08 | 2011-10-05 | GlaxoSmithKline Biologicals s.a. | Novel compounds derived from neisseria meningitidis |
ES2337650T3 (es) | 1999-03-12 | 2010-04-28 | Glaxosmithkline Biologicals S.A. | Polipeptidos antigenicos de neisseria meningitidis polinucleotidos y anticuerpos protectores correspondientes. |
DE60038166T2 (de) | 1999-03-19 | 2009-03-12 | Glaxosmithkline Biologicals S.A., Rixensart | Impfstoff gegen bakterielle antigene |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
CZ303515B6 (cs) | 1999-04-19 | 2012-11-07 | Smithkline Beecham Biologicals S. A. | Adjuvantní prostredek |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
GEP20053446B (en) | 1999-05-13 | 2005-02-25 | Wyeth Corp | Adjuvant Combination Formulations |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
CA2388337C (en) | 1999-10-22 | 2013-01-08 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
EP1104767A1 (en) | 1999-11-30 | 2001-06-06 | Stichting Dienst Landbouwkundig Onderzoek | Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups |
GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
ATE513913T1 (de) | 2000-05-10 | 2011-07-15 | Sanofi Pasteur Ltd | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
JP2004510746A (ja) * | 2000-10-06 | 2004-04-08 | パラディース,ハー.,ヘンリッヒ | 免疫調節効果を有する自家ワクチンとしてのカイバードラッグ |
PT1889630E (pt) | 2000-10-18 | 2012-02-29 | Glaxosmithkline Biolog Sa | Vacinas compreendendo o antigénio mage ligado a um fragmento da proteína d |
MX357775B (es) | 2000-10-27 | 2018-07-20 | J Craig Venter Inst Inc | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
US7048931B1 (en) * | 2000-11-09 | 2006-05-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
IL155690A0 (en) * | 2000-11-10 | 2003-11-23 | Wyeth Corp | Adjuvant combination formulations |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
CA2430379A1 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
ATE503493T1 (de) | 2001-02-23 | 2011-04-15 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
US20030031684A1 (en) | 2001-03-30 | 2003-02-13 | Corixa Corporation | Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA) |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
ES2607431T3 (es) | 2002-02-20 | 2017-03-31 | Glaxosmithkline Biologicals Sa | Micropartículas con moléculas que contienen polipéptidos adsorbidos |
US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
GB0206360D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
CA2489292A1 (en) | 2002-06-13 | 2003-12-24 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
SI2353608T1 (sl) | 2002-10-11 | 2020-12-31 | Glaxosmithkline Biologicals Sa | Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam |
CA2502268A1 (en) | 2002-10-23 | 2004-05-06 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
US7858098B2 (en) | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
CN102302776B (zh) | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
CN1798548B (zh) | 2003-06-02 | 2010-05-05 | 诺华疫苗和诊断公司 | 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物 |
GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
ATE474595T1 (de) | 2003-10-02 | 2010-08-15 | Glaxosmithkline Biolog Sa | B. pertussis antigene und ihre verwendung bei der vakzinierung |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
PT1961426E (pt) | 2003-10-02 | 2011-06-28 | Novartis Vaccines & Diagnostic | Vacinas combinadas contra a meningite |
WO2005107797A1 (en) | 2004-03-09 | 2005-11-17 | Chiron Corporation | Influenza virus vaccines |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
EP1740217B1 (en) | 2004-04-30 | 2011-06-15 | Novartis Vaccines and Diagnostics S.r.l. | Meningococcal conjugate vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
WO2006078294A2 (en) | 2004-05-21 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Alphavirus vectors for respiratory pathogen vaccines |
EP2269638A3 (en) | 2004-05-28 | 2012-06-13 | GlaxoSmithKline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
US7758866B2 (en) | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
US20090317420A1 (en) | 2004-07-29 | 2009-12-24 | Chiron Corporation | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
WO2006032500A2 (en) | 2004-09-22 | 2006-03-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP2923711A1 (en) * | 2004-11-03 | 2015-09-30 | Novartis Vaccines and Diagnostics, Inc. | Influenza vaccination |
US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
PL2682126T3 (pl) | 2005-01-27 | 2017-07-31 | Children's Hospital & Research Center At Oakland | Szczepionki pęcherzykowe oparte na GNA1870 dla szerokiego spektrum ochrony przeciwko chorobom spowodowanym przez Neisseria meningitidis |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
JP2008530195A (ja) * | 2005-02-16 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | リン酸アルミニウムおよび3d−mplを含むアジュバント組成物 |
GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
JP2008529558A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 髄膜炎/敗血症に関連する大腸菌由来のタンパク質および核酸 |
NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
GB0504436D0 (en) | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
NZ561822A (en) | 2005-03-23 | 2010-04-30 | Glaxosmithkline Biolog Sa | Multivalent influenza virus vaccine |
EP2329843A3 (en) | 2005-04-18 | 2011-09-14 | Novartis Vaccines and Diagnostics, Inc. | Expressing Hepatitis B Virus surface antigen for vaccine preparation |
DK2426141T3 (da) | 2005-04-29 | 2014-11-10 | Glaxosmithkline Biolog Sa | Fremgangsmåde til forebyggelse eller behandling af M tuberkuloseinfektioner |
GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
EP1945247A1 (en) | 2005-10-18 | 2008-07-23 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
AU2006310337B9 (en) | 2005-11-04 | 2013-11-28 | Novartis Ag | Adjuvanted influenza vaccines including cytokine-inducing agents |
EA014028B1 (ru) * | 2005-11-04 | 2010-08-30 | Новартис Вэксинс Энд Диагностикс Срл | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе в качестве адъюванта сплит вакцин против гриппа |
NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
PL2368572T3 (pl) | 2005-11-04 | 2020-11-16 | Seqirus UK Limited | Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej |
AU2006310339B2 (en) | 2005-11-04 | 2013-01-10 | Novartis Ag | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
EP2360175B1 (en) | 2005-11-22 | 2014-07-16 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
SI1962899T1 (sl) | 2005-12-22 | 2011-11-30 | Glaxosmithkline Biolog Sa | Pnevmokokna polisaharidna konjugatna vakcina |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
EA015561B1 (ru) | 2006-01-17 | 2011-08-30 | Арне Форсгрен | НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE) |
EP2478916B1 (en) | 2006-01-27 | 2020-04-01 | Seqirus UK Limited | Influenza vaccines containing hemagglutinin and matrix proteins |
CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
BRPI0710210A2 (pt) | 2006-03-30 | 2011-05-24 | Glaxomithkline Biolog S A | composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular |
US9839685B2 (en) | 2006-04-13 | 2017-12-12 | The Regents Of The University Of Michigan | Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen |
US10138279B2 (en) | 2006-04-13 | 2018-11-27 | Regents Of The University Of Michigan | Compositions and methods for Bacillus anthracis vaccination |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
ATE522541T1 (de) | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
EP2422810B1 (en) | 2006-07-17 | 2014-10-22 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine |
SG173363A1 (en) | 2006-07-18 | 2011-08-29 | Glaxosmithkline Biolog Sa | Vaccines for malaria |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
GB2453475B (en) | 2006-07-25 | 2011-01-19 | Secr Defence | Live vaccine strain |
EP2064230A2 (en) | 2006-08-16 | 2009-06-03 | Novartis AG | Immunogens from uropathogenic escherichia coli |
BRPI0716536A2 (pt) | 2006-09-11 | 2013-09-24 | Novartis Ag | produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos |
FI2068918T4 (fi) * | 2006-09-26 | 2024-08-16 | Access To Advanced Health Inst | Synteettistä adjuvanttia sisältävä rokotekoostumus |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
PL2601970T3 (pl) | 2006-09-29 | 2017-07-31 | Takeda Vaccines, Inc. | Preparaty szczepionki przeciw norowirusowi |
CA2664619C (en) | 2006-10-12 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent |
EP2086582B1 (en) | 2006-10-12 | 2012-11-14 | GlaxoSmithKline Biologicals s.a. | Vaccine comprising an oil in water emulsion adjuvant |
EP2121011B1 (en) | 2006-12-06 | 2014-05-21 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
EA021391B1 (ru) | 2007-03-02 | 2015-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
PE20090146A1 (es) | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | Composicion inmunogenica contra el virus influenza |
ES2626662T3 (es) | 2007-06-26 | 2017-07-25 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae |
CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
ES2539818T3 (es) * | 2007-08-02 | 2015-07-06 | Biondvax Pharmaceuticals Ltd. | Vacunas contra la gripe multiepitópicas multiméricas |
EP2185577A4 (en) | 2007-08-03 | 2010-09-22 | Harvard College | CHLAMYDIAN ANTIGENS |
BRPI0815199A2 (pt) | 2007-08-13 | 2015-03-31 | Glaxosmithkline Biolog Sa | Uso de um antígeno derivado da proteína circunsporozóite de plasmodium falciparum |
RU2471497C2 (ru) | 2007-09-12 | 2013-01-10 | Новартис Аг | Мутантные антигены gas57 и антитела против gas57 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
AU2008331800A1 (en) | 2007-12-03 | 2009-06-11 | President And Fellows Of Harvard College | Chlamydia antigens |
AU2008335457B2 (en) | 2007-12-07 | 2015-04-16 | Glaxosmithkline Biologicals S.A. | Compositions for inducing immune responses |
US10040825B2 (en) | 2007-12-19 | 2018-08-07 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
BRPI0821240B8 (pt) | 2007-12-21 | 2022-10-04 | Novartis Ag | formas mutantes de estreptolisina o |
EP3109258B1 (en) | 2007-12-24 | 2019-01-23 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
CA2716212A1 (en) | 2008-02-21 | 2009-08-27 | Novartis Ag | Meningococcal fhbp polypeptides |
US8506966B2 (en) * | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
EP2631245A1 (en) | 2008-03-10 | 2013-08-28 | Children's Hospital & Research Center at Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
JP5518041B2 (ja) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
HUE026586T2 (hu) | 2008-04-16 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Vakcina |
AU2009248810B2 (en) | 2008-05-23 | 2013-12-05 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
MX2011000668A (es) * | 2008-07-18 | 2011-07-29 | Id Biomedical Corp Quebec | Antigenos quimericos polipeptidicos del virus sincitial respiratorio. |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
CA2738245A1 (en) | 2008-09-26 | 2010-04-01 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US9974844B2 (en) | 2008-11-17 | 2018-05-22 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
KR20110091560A (ko) | 2008-12-03 | 2011-08-11 | 프로테아 벡신 테크놀로지스 엘티디. | 글루타밀 tRNA 합성효소(GtS) 단편들 |
KR101634058B1 (ko) | 2008-12-09 | 2016-06-27 | 화이자 백신스 엘엘씨 | IgE CH3 펩티드 백신 |
WO2010079081A1 (en) | 2009-01-07 | 2010-07-15 | Glaxosmithkline Biologicals S.A. | Methods for recovering a virus or a viral antigen produced by cell culture |
WO2010079464A1 (en) | 2009-01-12 | 2010-07-15 | Novartis Ag | Cna_b domain antigens in vaccines against gram positive bacteria |
GB0901423D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
GB0901411D0 (en) | 2009-01-29 | 2009-03-11 | Secr Defence | Treatment |
WO2010089339A1 (en) | 2009-02-06 | 2010-08-12 | Glaxosmithkline Biologicals S.A. | Purification of virus or viral antigens by density gradient ultracentrifugation |
EA023662B1 (ru) | 2009-02-10 | 2016-06-30 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
CA2752809A1 (en) | 2009-02-17 | 2010-08-26 | Glaxosmithkline Biologicals Sa | Inactivated dengue virus vaccine with aluminium-free adjuvant |
ES2671880T3 (es) | 2009-03-05 | 2018-06-11 | Jenny Colleen Mccloskey | Tratamiento de infección |
CA2754618A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Chlamydia antigens |
CN109248313B (zh) | 2009-04-14 | 2023-01-17 | 葛兰素史密丝克莱恩生物有限公司 | 用于免疫接种以抵御金黄色葡萄球菌的组合物 |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
BRPI1014494A2 (pt) | 2009-04-30 | 2016-08-02 | Coley Pharm Group Inc | vacina pneumocócica e usos da mesma |
PT2437753T (pt) * | 2009-06-05 | 2016-11-23 | Infectious Disease Res Inst | Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos |
GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
US9526778B2 (en) | 2009-06-15 | 2016-12-27 | Institut Pasteur De Lille | Influenza vaccine, composition, and methods of use |
EP2442827B1 (en) | 2009-06-16 | 2016-01-06 | The Regents of the University of Michigan | Nanoemulsion vaccines |
SI2445526T1 (sl) | 2009-06-24 | 2016-08-31 | Glaxosmithkline Biologicals S.A. | Rekombinantni RSV antigeni |
EP2445527A2 (en) | 2009-06-24 | 2012-05-02 | ID Biomedical Corporation of Quebec | Vaccine |
US10988511B2 (en) | 2009-07-07 | 2021-04-27 | Glaxosmithkline Biologicals Sa | Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens |
US20110305727A1 (en) | 2009-07-15 | 2011-12-15 | Novartis Ag | Rsv f protein compositions and methods for making same |
PT2464658E (pt) | 2009-07-16 | 2015-01-14 | Novartis Ag | Imunogénios de escherichia coli desintoxicados |
CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CA2772104A1 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
KR101660578B1 (ko) | 2009-09-03 | 2016-09-27 | 화이자 백신스 엘엘씨 | Pcsk9 백신 |
AU2010293902A1 (en) | 2009-09-10 | 2012-03-22 | Novartis Ag | Combination vaccines against respiratory tract diseases |
ES2538474T3 (es) | 2009-09-25 | 2015-06-22 | Glaxosmithkline Biologicals S.A. | Ensayo de inmunodifusión para el virus de la gripe |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
CA2776004A1 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
EP2493510B1 (en) | 2009-09-30 | 2020-07-08 | GlaxoSmithKline Biologicals SA | Conjugation of staphylococcus aureus type 5 and type 8 capsular polysaccharides |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
CA2779816A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
WO2011067758A2 (en) | 2009-12-02 | 2011-06-09 | Protea Vaccine Technologies Ltd. | Immunogenic fragments and multimers from streptococcus pneumoniae proteins |
DE102009056871A1 (de) * | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
AU2010334428B2 (en) | 2009-12-22 | 2015-05-21 | Celldex Therapeutics, Inc. | Vaccine compositions |
JP5781542B2 (ja) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | E.coliキャリアタンパク質に結合体化した多糖免疫原 |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
SG184188A1 (en) | 2010-03-26 | 2012-10-30 | Glaxosmithkline Biolog Sa | Hiv vaccine |
BR122021020829B8 (pt) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
JP2013529894A (ja) | 2010-04-07 | 2013-07-25 | ノバルティス アーゲー | パルボウイルスb19のウイルス様粒子を生成するための方法 |
US9597326B2 (en) | 2010-04-13 | 2017-03-21 | Glaxosmithkline Biologicals Sa | Benzonapthyridine compositions and uses thereof |
CN102858961A (zh) | 2010-05-03 | 2013-01-02 | 葛兰素史密丝克莱恩生物有限公司 | 新方法 |
EP2575988A1 (en) | 2010-05-28 | 2013-04-10 | Tetris Online, Inc. | Interactive hybrid asynchronous computer game infrastructure |
GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
CA2798837A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
CA2809463C (en) | 2010-09-27 | 2021-05-25 | Crucell Holland B.V. | Heterologous prime boost vaccination regimen against malaria |
KR20130139953A (ko) | 2010-09-27 | 2013-12-23 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
SG189176A1 (en) | 2010-10-15 | 2013-05-31 | Glaxosmithkline Biolog Sa | Cytomegalovirus gb antigen |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
FR2966044B1 (fr) * | 2010-10-18 | 2012-11-02 | Sanofi Pasteur | Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
EA025152B1 (ru) | 2010-12-02 | 2016-11-30 | Бионор Иммуно Ас | Конструкция пептидного каркаса |
UA110118C2 (uk) | 2010-12-14 | 2015-11-25 | Ґлаксосмітклайн Байолоджікалз С.А. | Мікобактеріальна антигенна композиція |
GB201022007D0 (en) | 2010-12-24 | 2011-02-02 | Imp Innovations Ltd | DNA-sensor |
EP2655389A2 (en) | 2010-12-24 | 2013-10-30 | Novartis AG | Compounds |
KR101993431B1 (ko) | 2011-01-06 | 2019-06-26 | 바이오노르 이뮤노 에이에스 | 단량체형 및 다량체형 면역원성 펩타이드 |
TR201908715T4 (tr) | 2011-01-26 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Rsv immünizasyon rejimi. |
WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
WO2012131504A1 (en) | 2011-03-02 | 2012-10-04 | Pfizer Inc. | Pcsk9 vaccine |
GB201106357D0 (en) | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
ES2782119T3 (es) | 2011-05-13 | 2020-09-10 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
SG194733A1 (en) | 2011-05-17 | 2013-12-30 | Glaxosmithkline Biolog Sa | Vaccine against streptococcus pneumoniae |
WO2013006569A2 (en) | 2011-07-01 | 2013-01-10 | The Regents Of The University Of California | Herpes virus vaccine and methods of use |
EP3332802A1 (en) | 2011-07-06 | 2018-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
WO2013006842A2 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
WO2013009564A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Tyrosine ligation process |
WO2013009849A1 (en) | 2011-07-11 | 2013-01-17 | Ligocyte Pharmaceuticals, Inc. | Parenteral norovirus vaccine formulations |
EP2736921B1 (en) | 2011-07-25 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Compositions and methods for assessing functional immunogenicity of parvovirus vaccines |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
SG11201400210RA (en) | 2011-09-01 | 2014-03-28 | Novartis Ag | Adjuvanted formulations of staphylococcus aureus antigens |
TR201909110T4 (tr) | 2011-09-14 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler. |
CA2848611A1 (en) | 2011-09-16 | 2013-03-21 | Ucb Pharma S.A. | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
CN104080479B (zh) | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
EP2780034A1 (en) | 2011-11-14 | 2014-09-24 | Crucell Holland B.V. | Heterologous prime-boost immunization using measles virus-based vaccines |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
WO2013131983A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
AU2013229465A1 (en) | 2012-03-07 | 2014-09-04 | Novartis Ag | Adjuvanted formulations of rabies virus immunogens |
JP2015509963A (ja) | 2012-03-08 | 2015-04-02 | ノバルティス アーゲー | Tlr4アゴニストを含む混合ワクチン |
CA2866406A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of booster vaccines |
EP2827891A1 (en) | 2012-03-18 | 2015-01-28 | GlaxoSmithKline Biologicals S.A. | Method of vaccination against human papillomavirus |
WO2013150518A1 (en) | 2012-04-01 | 2013-10-10 | Rappaport Family Institute For Research In The Medical Sciences | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659908A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
EP2844282B1 (en) | 2012-05-04 | 2019-06-12 | Pfizer Inc | Prostate-associated antigens and vaccine-based immunotherapy regimens |
BR112014028476A2 (pt) | 2012-05-16 | 2017-08-01 | Immune Design Corp | fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito |
SG11201407440WA (en) | 2012-05-22 | 2014-12-30 | Novartis Ag | Meningococcus serogroup x conjugate |
EP2666785A1 (en) | 2012-05-23 | 2013-11-27 | Affiris AG | Complement component C5a-based vaccine |
EP2859011B1 (en) | 2012-06-06 | 2019-12-11 | Bionor Immuno AS | Peptides derived from viral proteins for use as immunogens and dosage reactants |
EP2869842A1 (en) | 2012-07-06 | 2015-05-13 | Novartis AG | Immunogenic compositions and uses thereof |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
CA2882382A1 (en) | 2012-09-18 | 2014-03-27 | Novartis Ag | Outer membrane vesicles |
AU2013326584B2 (en) | 2012-10-02 | 2016-12-01 | Glaxosmithkline Biologicals Sa | Nonlinear saccharide conjugates |
MX2015002483A (es) | 2012-10-03 | 2016-01-08 | Glaxosmithkline Biolog Sa | Composiciones inmunogenicas. |
SG11201502599TA (en) | 2012-10-12 | 2015-05-28 | Glaxosmithkline Biolog Sa | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
DK2925355T3 (en) | 2012-11-30 | 2018-01-15 | Glaxosmithkline Biologicals Sa | PSEUDOMONAS ANTIGENES AND ANTIGEN COMBINATIONS |
AR093712A1 (es) | 2012-12-05 | 2015-06-17 | Glaxosmithkline Biologicals Sa | Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento |
HRP20240996T1 (hr) | 2013-03-13 | 2024-10-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefuzija rsv f proteina i njihova uporaba |
EP3608332B1 (en) | 2013-03-15 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Vaccine against human rhinovirus |
WO2014172637A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
CN105263517B (zh) | 2013-05-15 | 2021-03-26 | 阿尔伯达大学董事会 | E1e2hcv疫苗及使用方法 |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
CA2919773A1 (en) | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
ES2778928T3 (es) | 2013-08-30 | 2020-08-12 | Glaxosmithkline Biologicals Sa | Producción a gran escala de virus en cultivos celulares |
US10208102B2 (en) | 2013-11-01 | 2019-02-19 | University Of Oslo | Albumin variants and uses thereof |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
DK3069138T3 (en) | 2013-11-15 | 2019-04-08 | Univ Oslo Hf | CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF |
WO2015092710A1 (en) | 2013-12-19 | 2015-06-25 | Glaxosmithkline Biologicals, S.A. | Contralateral co-administration of vaccines |
NZ760783A (en) | 2014-01-21 | 2023-07-28 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
TW201620927A (zh) | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Uspa2蛋白質構築體及其用途 |
JP2017509713A (ja) * | 2014-03-25 | 2017-04-06 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー オブ ジ アーミー | アルミニウム塩に吸着させたワクチンの免疫賦活能を強化するための方法 |
MX377794B (es) | 2014-03-26 | 2025-03-10 | Glaxosmithkline Biologicals Sa | Antigenos estafilococicos mutantes. |
CN106659777A (zh) | 2014-06-13 | 2017-05-10 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合产品 |
DK3160500T3 (da) | 2014-06-25 | 2019-11-11 | Glaxosmithkline Biologicals Sa | Clostridium difficile immunogen sammensætning |
US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
AR101256A1 (es) | 2014-07-21 | 2016-12-07 | Sanofi Pasteur | Composición vacunal que comprende ipv y ciclodextrinas |
BR112017001417B1 (pt) | 2014-07-23 | 2023-11-07 | Children's Hospital & Research Center At Oakland | Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada |
US11083788B2 (en) | 2014-10-10 | 2021-08-10 | The Regents Of The University Of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
AU2015252119A1 (en) | 2014-11-07 | 2016-05-26 | Takeda Vaccines, Inc. | Hand, foot, and mouth vaccines and methods of manufacture and use thereof |
AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
MX387007B (es) | 2014-12-10 | 2025-03-19 | Glaxosmithkline Biologicals Sa | Una composición inmunogénica para usarse en el tratamiento o prevención de la infección por staphylococcus aureus. |
HRP20230416T1 (hr) | 2015-01-15 | 2023-07-07 | Pfizer Inc. | Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka |
EP4226937A3 (en) | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
US20180071380A1 (en) | 2015-03-20 | 2018-03-15 | The Regents Of The University Of Michigan | Immunogenic compositions for use in vaccination against bordetella |
JP2018521016A (ja) | 2015-06-03 | 2018-08-02 | アフィリス・アクチェンゲゼルシャフトAffiris Ag | IL−23−p19ワクチン |
EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
AU2016289497A1 (en) | 2015-07-07 | 2017-12-07 | Affiris Ag | Vaccines for the treatment and prevention of IgE mediated diseases |
JP6994453B2 (ja) | 2015-07-21 | 2022-01-14 | ファイザー・インク | コンジュゲート化莢膜糖類抗原を含む免疫原性組成物、それを含むキットおよびこれらの使用 |
JP7223989B2 (ja) | 2015-08-25 | 2023-02-17 | アグラワル,バビタ | 免疫調節組成物およびその使用方法 |
US11186615B2 (en) | 2015-10-08 | 2021-11-30 | The Governors Of The University Of Alberta | Hepatitis C virus E1/E2 heterodimers and methods of producing same |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
US10786561B2 (en) | 2015-11-20 | 2020-09-29 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2017109698A1 (en) | 2015-12-22 | 2017-06-29 | Glaxosmithkline Biologicals Sa | Immunogenic formulation |
SG11201807949WA (en) | 2016-03-14 | 2018-10-30 | Univ Oslo | Engineered immunoglobulins with altered fcrn binding |
WO2017158421A1 (en) | 2016-03-14 | 2017-09-21 | University Of Oslo | Anti-viral engineered immunoglobulins |
WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
US11780924B2 (en) | 2016-06-21 | 2023-10-10 | University Of Oslo | HLA binding vaccine moieties and uses thereof |
BR112019003462A2 (pt) | 2016-08-23 | 2019-06-25 | Glaxosmithkline Biologicals Sa | proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral |
GB201614799D0 (en) | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
EP3518966A1 (en) | 2016-09-29 | 2019-08-07 | GlaxoSmithKline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
GB201616904D0 (en) | 2016-10-05 | 2016-11-16 | Glaxosmithkline Biologicals Sa | Vaccine |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
JP7136777B2 (ja) | 2016-12-07 | 2022-09-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規プロセス |
GB201620968D0 (en) | 2016-12-09 | 2017-01-25 | Glaxosmithkline Biologicals Sa | Adenovirus polynucleotides and polypeptides |
MX2019006349A (es) | 2016-12-16 | 2019-08-22 | Inst Res Biomedicine | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
PL3570879T3 (pl) | 2017-01-20 | 2022-06-20 | Pfizer Inc. | Kompozycje immunogenne do zastosowania w szczepionkach przeciw pneumokokom |
BR112019020209A2 (pt) | 2017-03-31 | 2020-06-02 | Glaxosmithkline Intellectual Property Development Limited | Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação. |
WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
US20200093909A1 (en) | 2017-04-19 | 2020-03-26 | Institute For Research In Biomedicine | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to |
WO2018198085A1 (en) | 2017-04-28 | 2018-11-01 | Glaxosmithkline Biologicals Sa | Vaccination |
GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
IE20190085A3 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
BR112020001768A2 (pt) | 2017-08-14 | 2020-09-29 | Glaxosmithkline Biologicals S.A. | método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação. |
WO2019048936A1 (en) | 2017-09-07 | 2019-03-14 | University Of Oslo | VACCINE MOLECULES |
WO2019048928A1 (en) | 2017-09-07 | 2019-03-14 | University Of Oslo | VACCINE MOLECULES |
JP7339942B2 (ja) | 2017-09-08 | 2023-09-06 | アクセス ツー アドバンスト ヘルス インスティチュート | サポニンを含むリポソーム製剤および使用方法 |
JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス, インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
CA3081586A1 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
US11702674B2 (en) | 2018-06-12 | 2023-07-18 | Glaxosmithkline Biologicals Sa | Simian adenovirus vectors comprising the ChAd-157 fiber protein |
EP3581201A1 (en) | 2018-06-15 | 2019-12-18 | GlaxoSmithKline Biologicals S.A. | Escherichia coli o157:h7 proteins and uses thereof |
CN110680909B (zh) * | 2018-07-04 | 2024-09-20 | 辽宁成大生物股份有限公司 | 一种速释b型流感嗜血杆菌结合疫苗可溶性微针贴及其制备方法 |
CA3106304A1 (en) | 2018-07-31 | 2020-02-06 | Glaxosmithkline Biologicals Sa | Antigen purification method |
CN112601545A (zh) | 2018-08-07 | 2021-04-02 | 葛兰素史密丝克莱恩生物有限公司 | 工艺和疫苗 |
US20210220462A1 (en) | 2018-08-23 | 2021-07-22 | Glaxosmithkline Biologicals Sa | Immunogenic proteins and compositions |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CN113166733B (zh) | 2018-11-16 | 2024-12-31 | 港大科桥有限公司 | 活减毒流感b病毒组合物及其制备和使用方法 |
US20220000779A1 (en) | 2018-12-06 | 2022-01-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
JP7585203B2 (ja) | 2018-12-12 | 2024-11-18 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用 |
US20220184158A1 (en) | 2018-12-21 | 2022-06-16 | Glaxosmithkline Biologicals Sa | Methods of inducing an immune response |
JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
CN113573730A (zh) | 2019-03-05 | 2021-10-29 | 葛兰素史密斯克莱生物公司 | 乙型肝炎免疫方案和组合物 |
WO2020208502A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
WO2020212461A1 (en) | 2019-04-18 | 2020-10-22 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
EP4004018A1 (en) | 2019-07-24 | 2022-06-01 | GlaxoSmithKline Biologicals SA | Modified human cytomegalovirus proteins |
WO2021023691A1 (en) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
MX2022001489A (es) | 2019-08-05 | 2022-03-02 | Glaxosmithkline Biologicals Sa | Proceso para la preparacion de una composicion que comprende un polipeptido de proteina d. |
EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
EP4028051A1 (en) | 2019-09-09 | 2022-07-20 | GlaxoSmithKline Biologicals S.A. | Immunotherapeutic compositions |
CN114667343A (zh) | 2019-11-01 | 2022-06-24 | 辉瑞大药厂 | 大肠杆菌组合物及其方法 |
WO2021122551A1 (en) | 2019-12-19 | 2021-06-24 | Glaxosmithkline Biologicals Sa | S. aureus antigens and compositions thereof |
CA3165957A1 (en) | 2020-01-24 | 2021-07-29 | Thomas K. EQUELS | Methods, compositions, and vaccines for treating a virus infection |
US20230109142A1 (en) | 2020-02-14 | 2023-04-06 | Immunor As | Corona virus vaccine |
WO2021165847A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
WO2021165928A2 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CA3181627A1 (en) | 2020-05-05 | 2021-11-11 | Glaxosmithkline Biologicals Sa | Microfluidic mixing device and methods of use |
WO2022029024A1 (en) | 2020-08-03 | 2022-02-10 | Glaxosmithkline Biologicals Sa | Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof |
EP4237428A2 (en) | 2020-10-27 | 2023-09-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
AU2021373358A1 (en) | 2020-11-04 | 2023-06-01 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
MX2023006320A (es) | 2020-12-02 | 2023-06-14 | Glaxosmithkline Biologicals Sa | Cadena donante complementada fimh. |
US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
US20240299510A1 (en) | 2020-12-31 | 2024-09-12 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
MX2023009456A (es) | 2021-02-11 | 2023-08-28 | Glaxosmithkline Biologicals Sa | Preparacion de la vacuna contra el vph. |
IL305313A (en) | 2021-02-19 | 2023-10-01 | Sanofi Pasteur | Meningococcal b recombinant vaccine |
JP2024510717A (ja) | 2021-02-22 | 2024-03-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物、使用及び方法 |
WO2022232375A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
WO2022249107A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
JP2024522395A (ja) | 2021-05-28 | 2024-06-19 | ファイザー・インク | コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用 |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
CN118434441A (zh) | 2021-11-18 | 2024-08-02 | 马特里瓦克斯公司 | 免疫原性融合蛋白组合物和其使用方法 |
AU2023207315A1 (en) | 2022-01-13 | 2024-06-27 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023144665A1 (en) | 2022-01-28 | 2023-08-03 | Glaxosmithkline Biologicals Sa | Modified human cytomegalovirus proteins |
US20250163484A1 (en) | 2022-02-25 | 2025-05-22 | Pfizer Inc. | Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides |
CN119317445A (zh) | 2022-05-11 | 2025-01-14 | 辉瑞公司 | 用于生产含有防腐剂的疫苗制剂的方法 |
GB202215634D0 (en) | 2022-10-21 | 2022-12-07 | Glaxosmithkline Biologicals Sa | Polypeptide scaffold |
WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
CN120265317A (zh) | 2022-11-22 | 2025-07-04 | 辉瑞公司 | 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途 |
IL321069A (en) | 2022-12-01 | 2025-07-01 | Pfizer | Pneumococcal conjugate vaccine preparations |
WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
WO2024160901A1 (en) | 2023-02-02 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024214016A1 (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US703355A (en) * | 1901-11-05 | 1902-06-24 | Bertt H Brockway | Current-motor. |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4196192A (en) * | 1977-10-28 | 1980-04-01 | American Cyanamid Company | Combined Haemophilus influenzae type b and pertussis vaccine |
US4620978A (en) * | 1982-04-07 | 1986-11-04 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis A virus purified and triply cloned |
GB8508685D0 (en) * | 1985-04-03 | 1985-05-09 | Minor P D | Peptides |
US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US4806352A (en) * | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
US5026557A (en) * | 1987-09-09 | 1991-06-25 | The Liposome Company, Inc. | Adjuvant composition |
JPH085804B2 (ja) * | 1988-04-28 | 1996-01-24 | 財団法人化学及血清療法研究所 | A型及びb型肝炎混合アジュバントワクチン |
US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
DE3916595A1 (de) * | 1989-05-22 | 1990-11-29 | Boehringer Mannheim Gmbh | Verfahren zur nichtradioaktiven messung der nucleinsaeuresynthese in eukaryontischen zellen |
DE69031556T2 (de) * | 1989-07-25 | 1998-05-14 | Smithkline Beecham Biologicals S.A., Rixensart | Antigene sowie Verfahren zu deren Herstellung |
US5100662A (en) * | 1989-08-23 | 1992-03-31 | The Liposome Company, Inc. | Steroidal liposomes exhibiting enhanced stability |
CH678394A5 (ko) * | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
EP0550485A1 (en) * | 1990-09-28 | 1993-07-14 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | DERIVATIVES OF gp160 AND VACCINES BASED ON gp160 OR A DERIVATIVE THEREOF, CONTAINING AN ADJUVANT |
GB9106048D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
AU9052091A (en) * | 1990-12-20 | 1992-07-22 | Smithkline Beecham Biologicals (Sa) | Vaccines based on hepatitis b surface antigen |
GB9028038D0 (en) * | 1990-12-24 | 1991-02-13 | Nycomed Pharma As | Test method and reagent kit therefor |
GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
MY111880A (en) * | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
CA2156525A1 (en) * | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
-
1994
- 1994-03-14 US US08/525,638 patent/US5776468A/en not_active Expired - Lifetime
- 1994-03-14 BR BR9405957A patent/BR9405957A/pt not_active Application Discontinuation
- 1994-03-14 SG SG1996008821A patent/SG48309A1/en unknown
- 1994-03-14 NZ NZ263538A patent/NZ263538A/en not_active IP Right Cessation
- 1994-03-14 CN CN94191582A patent/CN1087176C/zh not_active Expired - Lifetime
- 1994-03-14 WO PCT/EP1994/000818 patent/WO1994021292A1/en active IP Right Grant
- 1994-03-14 EP EP97101617A patent/EP0812593B8/en not_active Expired - Lifetime
- 1994-03-14 SK SK1173-95A patent/SK117395A3/sk unknown
- 1994-03-14 AU AU64264/94A patent/AU685443B2/en not_active Expired
- 1994-03-14 AT AT94911894T patent/ATE157882T1/de active
- 1994-03-14 KR KR1019950704133A patent/KR100310510B1/ko not_active Expired - Lifetime
- 1994-03-14 ES ES97101617T patent/ES2162139T5/es not_active Expired - Lifetime
- 1994-03-14 DK DK97101617T patent/DK0812593T4/da active
- 1994-03-14 JP JP52064094A patent/JP4028593B2/ja not_active Expired - Lifetime
- 1994-03-14 PL PL94310598A patent/PL178578B1/pl unknown
- 1994-03-14 ES ES94911894T patent/ES2109685T5/es not_active Expired - Lifetime
- 1994-03-14 CZ CZ19952467A patent/CZ289476B6/cs not_active IP Right Cessation
- 1994-03-14 AT AT97101617T patent/ATE204762T1/de active
- 1994-03-14 DE DE69405551T patent/DE69405551T3/de not_active Expired - Lifetime
- 1994-03-14 HU HU9501979A patent/HU219056B/hu unknown
- 1994-03-14 DE DE69428136T patent/DE69428136T3/de not_active Expired - Lifetime
- 1994-03-14 PT PT97101617T patent/PT812593E/pt unknown
- 1994-03-14 EP EP01112703A patent/EP1175912A1/en not_active Ceased
- 1994-03-14 DK DK94911894T patent/DK0689454T4/da active
- 1994-03-14 EP EP94911894A patent/EP0689454B2/en not_active Expired - Lifetime
- 1994-03-21 AP APAP/P/1994/000629A patent/AP515A/en active
- 1994-03-21 DZ DZ940026A patent/DZ1763A1/fr active
- 1994-03-21 IL IL109056A patent/IL109056A/en not_active IP Right Cessation
- 1994-03-21 MA MA23451A patent/MA23143A1/fr unknown
- 1994-06-05 SA SA94140762A patent/SA94140762B1/ar unknown
-
1995
- 1995-09-22 FI FI954514A patent/FI110844B/fi not_active IP Right Cessation
- 1995-09-22 NO NO19953759A patent/NO322578B1/no not_active IP Right Cessation
-
1997
- 1997-11-26 GR GR970403132T patent/GR3025483T3/el unknown
-
2002
- 2002-07-30 HK HK02105614.3A patent/HK1045935A1/en unknown
-
2004
- 2004-08-05 JP JP2004229276A patent/JP4837906B2/ja not_active Expired - Lifetime
-
2005
- 2005-10-12 NO NO20054701A patent/NO20054701D0/no not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US703355A (en) * | 1901-11-05 | 1902-06-24 | Bertt H Brockway | Current-motor. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100310510B1 (ko) | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 | |
RU2121849C1 (ru) | Вакцинная композиция против гепатита, способ профилактики гепатита | |
AP408A (en) | Vaccine composition containing adjuvants. | |
JP4125781B2 (ja) | ワクチン | |
JP3881015B2 (ja) | B型肝炎ワクチン | |
KR19990008003A (ko) | 사포닌 및 스테롤을 함유한 백신 | |
AU705739B2 (en) | A method of preparing vaccine compositions containing 3-0-deacylated monophosphoryl lipid A | |
CA2555911C (en) | Adjuvant compositions containing 3-o deacylated monophosphoryl lipid a | |
CA2157376C (en) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a | |
AU687494C (en) | Vaccines | |
HK1011930B (en) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a | |
HK1011930C (en) | Vaccine compositions containing 3-o deacylated monophosphoryl lipid a | |
HK1023499B (en) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a | |
HK1060297A (en) | Vaccines containing a saponin and a sterol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 19950923 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19990313 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20010223 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20010629 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20010918 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20010919 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
PR1001 | Payment of annual fee |
Payment date: 20040719 Start annual number: 4 End annual number: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20050722 Start annual number: 5 End annual number: 5 |
|
PR1001 | Payment of annual fee |
Payment date: 20060714 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20070718 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20080711 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20090716 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20100827 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20110830 Start annual number: 11 End annual number: 11 |
|
FPAY | Annual fee payment |
Payment date: 20120830 Year of fee payment: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20120830 Start annual number: 12 End annual number: 12 |
|
FPAY | Annual fee payment |
Payment date: 20130830 Year of fee payment: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20130830 Start annual number: 13 End annual number: 13 |
|
EXPY | Expiration of term | ||
PC1801 | Expiration of term |
Termination date: 20140914 Termination category: Expiration of duration |